


FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P0998D1Serial No.  
09/273,230Applicant  
Cleland et al.Filing Date  
18 Mar 1999Group  
1642

# LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
EB	62	4,753,894	28.06.88	Frankel et al.			06.03.92
	63	4,943,533	24.07.90	Mendelsohn et al.			
	64	4,968,603	06.11.90	Slamon et al.			
	65	4,975,278	04.12.90	Senter, P. et al.			
	66	5,169,774	08.12.92	Frankel et al.			
	67	5,183,884	02.02.93	Kraus et al.			
	68	5,367,060	22.11.94	Vandlen et al.			
	69	5,464,751	07.11.95	Greene et al.			
	70	5,480,968	02.01.96	Kraus et al.			
	71	5,641,869	24.06.97	Vandlen et al.			
	72	5,677,171	14.10.97	Hudziak et al.			
	73	5,720,937	24.02.98	Hudziak et al.			
	74	5,720,954	24.02.98	Hudziak et al.			
	75	5,747,261	05.05.98	King et al.			
	76	5,770,195	23.06.98	Hudziak et al.			
	77	5,772,997	30.06.98	Hudziak et al.			
	78	5,776,427	07.07.98	Thorpe et al.			
	79	5,783,186	21.07.98	Arakawa et al.			
	80	5,824,311	20.10.98	Greene et al.			
	81	5,834,229	10.11.98	Vandlen et al.			
	82	5,840,525	24.11.98	Vandlen et al.			
	83	5,856,110	05.01.99	Vandlen et al.			
	84	5,859,206	12.01.99	Vandlen et al.			
	85	5,985,553	16.11.99	King et al.			
	86	6,015,567	18.01.00	Hudziak et al.			
	87	6,028,059	22.02.00	Curriel et al.			
	88	6,054,561	25.04.00	Ring			07.06.95

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
EB	89	599,274	01.06.94	EPO			
	90	WO 89/06692	27.07.89	PCT			
	91	WO 94/00136	06.01.94	PCT			
	92	WO 94/22478	13.10.94	PCT			
	93	WO 97/20858	12.06.97	PCT			


Examiner

Date Considered

9/19/00

\*Examiner: If reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P0998D1Serial No.  
09/273,230

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant  
Cleland et al.Filing Date  
18 Mar 1999Group  
1642

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

94	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB" <u>British Journal of Cancer</u> 57(4):358-363 (Apr 1988)
95	Adams and Weiner, "Intracellular single-chain Fv antibodies--a knockout punch for neoplastic cells?" <u>Gynecologic Oncology</u> 59(1):6-7 (Oct 1995)
96	Arboleda et al., "Effects of the 4D5 antibody on HER2/neu heterodimerization with other class I receptors in human breast cancer cells" <u>Proceedings of the American Association for Cancer Research</u> (Abstract #353) 37:51 (Mar 1996)
97	Arteaga et al., "p185 <sup>c-erbB-2</sup> Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <u>Cancer Research</u> 54(14):3758-3765 (Jul 15, 1994)
98	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <u>Molecular Carcinogenesis</u> 3(6):350-362 (1990)
99	Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992)
100	Baselga et al., "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994)
101	Borst et al., "Oncogene Alterations in Endometrial Carcinoma" <u>Gynecologic Oncology</u> 38(3):364-366 (Sep 1990)
102	Carraway et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling" <u>Cell</u> 78:5-8 (Jul 15, 1994)
103	Carter et al., "Humanization of an anti-p185 <sup>HER2</sup> antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (May 1992)
104	Cohen et al., "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185 <sup>neu</sup> ) in normal and transformed epithelial tissues of the digestive tract" <u>Oncogene</u> 4(1):81-88 (Jan 1989)
105	D'souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994)
106	Darzynkiewicz et al., "Features of apoptotic cells measured by flow cytometry" <u>Cytometry</u> 13(8):795-808 (1992)
107	De Santes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein" <u>Cancer Research</u> 52:1916-1923 (1992)
108	Deshane et al., "Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis" <u>Cancer Gene Therapy</u> 3(2):89-98 (Mar-Apr 1996)
109	Deshane et al., "Intracellular antibody knockout of the ERBB2 oncoprotein achieves targeted eradication of tumor targets by induction of apoptosis" <u>Journal of Investigative Medicine</u> 43(Suppl. 2):328A (1995)
110	Deshane et al., "Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody" <u>Gynecologic Oncology</u> 59(1):8-14 (Oct 1995)
111	Deshane et al., "Targeted tumor killing via an intracellular antibody against erbB-2" <u>Journal of Clinical Investigation</u> 96(6):2980-2989 (Dec 1995)
112	Deshane et al., "Transductional Efficacy and Safety of an Intraperitoneally Delivered Adenovirus Encoding an Anti-erbB-2 Intracellular Single-Chain Antibody for Ovarian Cancer Gene Therapy" <u>Gynecologic Oncology</u> 64(3):378-385 (Mar 1997)

Examiner

Date Considered

9/19/00

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

SEP 12 2000

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P0998D1

Serial No.

09/273,230

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cleland et al.

Filing Date

18 Mar 1999

Group

1642

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

113	Digiesi et al., "Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2" <u>Hybridoma</u> 11(4):519-527 (Aug 1992)
114	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (Jul 1985)
115	Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen" <u>Proc. Natl. Acad. Sci.</u> 83:9129-9133 (1986)
116	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" <u>Oncogene</u> 2:273-277 (1988)
117	Drebin et al., "Monoclonal Antibodies Specific for the neu Oncogene Product Directly Mediate Anti-tumor Effects In Vivo" <u>Oncogene</u> 2(4):387-394 (1988)
118	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)
119	Fraker and Speck Jr., "Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril" <u>Biochemical &amp; Biophysical Research Communications</u> 80(4):849-857 (Feb 28, 1978)
120	Fukushige et al., "Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line" <u>Molecular &amp; Cellular Biology</u> 6(3):955-958 (Mar 1986)
121	(Genentech, Inc. Proposal Request and Material Transfer Agreement with Richard H. Scheuermann (1993), 3 pages, and letters in relation to it dated June 23, 1993 and October 20, 1993)
122	Grim et al., "The level of erbB2 expression predicts sensitivity to the cytotoxic effects of an intracellular anti-erbB2 sFv" <u>Journal of Molecular Medicine</u> 76(6):451-458 (May 1998)
123	Groenen et al., "Structure-Function Relationships for the EGF/TGF- $\alpha$ Family of Mitogens" <u>Growth Factors</u> 11:235-257 (1994)
124	Guerin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <u>Oncogene Res</u> 3:21-31 (1988)
125	Hancock et al., "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (Sep 1, 1991)
126	Harwerth et al., "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 25, 1992)
127	Hudziak et al., "Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells" <u>Proc. Natl. Acad. Sci.</u> 84(20):7159-7163 (Oct 1987)
128	Hudziak et al., "p185HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular &amp; Cellular Biology</u> 9(3):1165-1172 (Mar 1989)
129	Ilgen et al., "Characterization of anti-HER/2 antibodies which inhibit the growth of breast tumor cells in vitro" <u>Proceedings of the American Association for Cancer Research</u> (abstract #3209) 37:470 (Mar 1996)
130	Ilgen et al., "Characterization of anti-HER/2 monoclonal antibodies which inhibit the growth of breast cancer cell lines in vitro" <u>Proceedings of the American Association for Cancer Research</u> (Abstract #564) 38:84 (Mar 1997)
131	Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992)
132	Kern et al., "p185neu Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <u>Cancer Research</u> 50(16):5184-5191 (Aug 15, 1990)


Examiner

Date Considered

9/19/00

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P0998D1

Serial No.

09/273,230

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cleland et al.

Filing Date

18 Mar 1999

Group

1642

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

133	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (Sept 1985)
134	Kita et al., "ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies" <u>Biochemical &amp; Biophysical Research Communications</u> 226(1):59-69 (Sep 4, 1996)
135	Klapper et al., "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors" <u>Oncogene</u> 14:2099-2109 (1997)
136	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed Against the Extracellular Domain of the HER2/ERBB2 Protooncogene" (poster presented at the Annual Meeting of the Tissue Culture Association held in Houston, Texas on June 1990) pps. 1-13
137	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990)
138	Kotts et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-Gamma and Monoclonal Antibodies Directed Against the Extracellular Domain of the Her2/erbB2 Oncogene Protein" <u>FASEB Journal</u> (abstract #1470) 4(7):A1946 (1990)
139	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <u>Molecular &amp; Cellular Biology</u> 11(2):979-986 (Feb 1991)
140	Lee et al., "Transforming Growth Factor $\alpha$ : Expression, Regulation, and Biological Activities" <u>Pharmacological Reviews</u> 47(1):51-85 (Mar 1995)
141	Lemke, G., "Neuregulins in Development" <u>Molecular and Cellular Neuroscience</u> 7:247-262 (1996)
142	Levi et al., "The Influence of Heregulins on Human Schwann Cell Proliferation" <u>J. Neuroscience</u> 15(2):1329-1340 (Feb 1995)
143	Lewis et al., "Differential responses of human tumor cell lines to anti-p185 <sup>HER2</sup> monoclonal antibodies" <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993)
144	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)
145	Maier et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991)
146	Marth et al., "Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells" <u>International Journal of Cancer</u> 50(1):64-68 (Jan 2, 1992)
147	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984)
148	Masuko et al., "A murine Monoclonal Antibody That Recognizes an Extracellular Domain of the Human c-erbB-2 Protooncogene Product" <u>Jpn J. Cancer Res.</u> 80:10-14 (January 1989)
149	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <u>Cancer</u> 65(1):88-92 (Jan 1, 1990)
150	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" <u>Oncogene</u> 4:543-548 (1989)
151	Moore et al., "Apoptosis in CHO Cell Batch Cultures: Examination by Flow Cytometry" <u>Cytotechnology</u> 17:1-11 (1995)
152	Morrissey et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185 <sup>erbB2</sup> " <u>Proc. Natl. Acad. Sci. USA</u> 92:1431-1435 (Feb 1995)


Examiner

Date Considered

9/19/2000

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P0998D1

Serial No.

09/273,230

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Cleland et al.

Filing Date

18 Mar 1999

Group

1642

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

153	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185neu" <u>Methods in Enzymology</u> 198:277-290 (1991)
154	Park et al., "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" <u>Cancer Research</u> 49(23):6605-6609 (Dec 1, 1989)
155	Pickler et al., "Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition" <u>Journal of Immunology</u> 150(3):1105-1121 (Feb 1, 1993)
156	Pietras et al., "Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells" <u>Oncogene</u> 9:1829-1838 (1994)
157	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180 <sup>erbB4</sup> " <u>Nature</u> (Letters to Nature) 366:473-475 (Dec 2, 1993)
158	Plowman et al., "Ligand-specific activation of HER4/p180 <sup>erbB4</sup> , a fourth member of the epidermal growth factor receptor family" <u>Proc. Natl. Acad. Sci. USA</u> 90:1746-1750 (Mar 1993)
159	Price et al., "Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice" <u>Cancer Research</u> 50(3):717-721 (Feb 1, 1990)
160	Ring et al., "Distribution and Physical Properties of BCA200, a M <sub>r</sub> 200,000 Glycoprotein Selectively Associated with Human Breast Cancer" <u>Cancer Research</u> 49:3070-3080 (Jun 1, 1989)
161	Ring et al., "Identity of BCA200 and c-erbB-2 Indicated by Reactivity of Monoclonal Antibodies with Recombinant c-erbB-2" <u>Molecular Immunology</u> 28(8):915-917 (1991)
162	Rodeck et al., "Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors" <u>J. Cellular Biochem.</u> 35(4):315-320 (1987)
163	Sarup et al., "Characterization of an Anti-P185 <sup>HER2</sup> Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991)
164	Scheuermann, R., "Anti-HER2 Effects" (slide which may have been (but was probably not) presented at a seminar by Scheuermann at Syntex on August 3, 1994)
165	Schlom, J., "Monoclonal Antibodies: They're More and Less Than You Think" <u>Molecular Foundations of Oncology</u> , Broder, S. ed., Baltimore, MD:Williams & Wilkins, Chapter 6, pps. 95-134 (1991)
166	Scott et al., "p185 <sup>HER2</sup> Signal Transduction in Breast Cancer Cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991)
167	Shawver et al., "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994)
168	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991)
169	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)
170	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)
171	Sliwkowski et al., "A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer" <u>Proceedings of the American Association for Cancer Research</u> 37:625-626 (Mar 1996)
172	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994)

Examiner

Date Considered

9/19/00

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.